To further highlight the therapeutic potential of ERK inhibitors in such disorders, a drug belonging to the class, known as PD-901, has shown promise in inhibiting Tau hyperphosphorylation which is associated with Alzheimer’s Disease (Medina et al. 2019)⁠ Moreover, plastoquinonyl-decyltriphenylphosphonium, known more commonly as SkQ1, which is a mitochondria-targeted antioxidant, has also shown efficacy in preventing this hyperphosphorylation, once again through ERK inhibition (Muraleva et al. 2021). The gene discussed is MAPK1; the disease is early-onset autosomal dominant Alzheimer disease.